MRNA - Moderna - Stock Price & Dividends

Moderna, Inc. is a biotechnology company that pioneers the development of messenger RNA (mRNA) therapeutics and vaccines to combat a wide range of diseases and conditions. The company's innovative approach focuses on harnessing the power of mRNA to instruct cells to produce specific proteins, enabling the body to fight diseases more effectively.

Moderna's vaccine portfolio is extensive, covering respiratory diseases such as COVID-19, influenza, and respiratory syncytial virus, as well as latent diseases like cytomegalovirus, epstein-barr virus, and human immunodeficiency virus. The company is also working on public health vaccines for diseases like Zika, Nipah, and Mpox, as well as infectious diseases like Lyme and norovirus.

In addition to vaccines, Moderna is developing various therapeutics, including systemic secreted and cell surface therapeutics, cancer vaccines, and intratumoral immuno-oncology products. The company is also exploring rare disease intracellular therapeutics and inhaled pulmonary therapeutics, demonstrating its commitment to addressing a broad spectrum of health challenges.

Moderna has established strategic alliances and collaborations with leading pharmaceutical companies, research institutions, and government agencies, including AstraZeneca, Merck & Co., Inc, Vertex Pharmaceuticals, and the Bill & Melinda Gates Foundation. These partnerships enable the company to leverage its mRNA technology to accelerate the development of new treatments and vaccines.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna, Inc. has undergone significant growth and transformation, changing its name from Moderna Therapeutics, Inc. in 2018. Today, the company is at the forefront of mRNA research and development, driving innovation and advancing the field of biotechnology.